dc.contributor.author
Ünlü, Sinem
dc.contributor.author
Lachmann, Nils
dc.contributor.author
Jara, Maximilian
dc.contributor.author
Ritschl, Paul Viktor
dc.contributor.author
Wiering, Leke
dc.contributor.author
Eurich, Dennis
dc.contributor.author
Denecke, Christian
dc.contributor.author
Biebl, Matthias
dc.contributor.author
Chopra, Sascha
dc.contributor.author
Gül-Klein, Safak
dc.contributor.author
Schöning, Wenzel
dc.contributor.author
Schmelzle, Moritz
dc.contributor.author
Reinke, Petra
dc.contributor.author
Tacke, Frank
dc.contributor.author
Pratschke, Johann
dc.contributor.author
Öllinger, Robert
dc.contributor.author
Dziodzio, Tomasz
dc.date.accessioned
2021-04-23T08:16:51Z
dc.date.available
2021-04-23T08:16:51Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/30500
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-30240
dc.description.abstract
Donor-specific anti-human leukocyte antigen antibodies (DSA) are controversially discussed in the context of liver transplantation (LT). We investigated the relationship between the presence of DSA and the outcome after LT. All the LTs performed at our center between 1 January 2008 and 31 December 2015 were examined. Recipients < 18 years, living donor-, combined, high-urgency-, and re-transplantations were excluded. Out of 510 LTs, 113 DSA-positive cases were propensity score-matched with DSA-negative cases based on the components of the Balance of Risk score. One-, three-, and five-year survival after LT were 74.3% in DSA-positive vs. 84.8% (p = 0.053) in DSA-negative recipients, 71.8% vs. 71.5% (p = 0.821), and 69.3% vs. 64.9% (p = 0.818), respectively. Rejection therapy was more often applied to DSA-positive recipients (n = 77 (68.1%) vs. 37 (32.7%) in the control group, p < 0.001). At one year after LT, 9.7% of DSA-positive patients died due to sepsis compared to 1.8% in the DSA-negative group (p = 0.046). The remaining causes of death were comparable in both groups (cardiovascular 6.2% vs. 8.0%; p = 0.692; hepatic 3.5% vs. 2.7%, p = 0.788; malignancy 3.5% vs. 2.7%, p = 0.788). DSA seem to have an indirect effect on the outcome of adult LTs, impacting decision-making in post-transplant immunosuppression and rejection therapies and ultimately increasing mortality due to infectious complications.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
survival analysis
en
dc.subject
rejection treatment
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Treatment of Anti-HLA Donor-Specific Antibodies Results in Increased Infectious Complications and Impairs Survival after Liver Transplantation
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
3986
dcterms.bibliographicCitation.doi
10.3390/jcm9123986
dcterms.bibliographicCitation.journaltitle
Journal of Clinical Medicine
dcterms.bibliographicCitation.number
12
dcterms.bibliographicCitation.originalpublishername
MDPI AG
dcterms.bibliographicCitation.volume
9
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33317012
dcterms.isPartOf.eissn
2077-0383